Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting epigenetic modifiers in cancer.

A F Holloway1, P C Oakford

  • 1Menzies Research Institute, University of Tasmania, Hobart, Tasmania 7001, Australia. A.F.Holloway@utas.edu.au

Current Medicinal Chemistry
|November 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Epigenetic Regulation in Transcriptional Memory in the Immune System.

Advances in protein chemistry and structural biology·2017
Same author

Reversing aberrant methylation patterns in cancer.

Current medicinal chemistry·2010
Same author

Determinants of a transcriptionally competent environment at the GM-CSF promoter.

Nucleic acids research·2008
Same author

Regulation of cytokine gene transcription in the immune system.

Molecular immunology·2002
Same author

Functional interaction between the HIV transactivator Tat and the transcriptional coactivator PC4 in T cells.

The Journal of biological chemistry·2000
Same author

Localisation and expression of metallothionein immunoreactivity in the developing sheep brain.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·1997
Same journal

Computational Study of ADME-TOx from Selected Phytocompounds of Solanum tuberosum and Cucumis sativus.

Current medicinal chemistry·2026
Same journal

QSAR-Based Strategies for Selective-HDAC6 Inhibitor Development: A Detailed Review.

Current medicinal chemistry·2026
Same journal

Breaking New Ground in Oncology: FDA Acceptance of Vepdegestrant NDA Marks a Milestone for PROTAC Therapies in Breast Cancer.

Current medicinal chemistry·2026
Same journal

Knockdown of circFGFR2 inhibits prostate cancer cell metastasis and proliferation by targeting miR-221-5p/ SMUG1 pathway.....

Current medicinal chemistry·2026
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
See all related articles

Epigenetic modifications regulate gene expression and are crucial in cancer. Inhibitors targeting these epigenetic complexes offer promising, reversible therapeutic strategies for cancer treatment.

Area of Science:

  • Molecular Biology
  • Epigenetics
  • Cancer Biology

Background:

  • Gene expression is regulated by chromatin structure, influenced by epigenetic modifications.
  • Epigenetic changes, alongside genetic alterations, contribute to aberrant gene expression in cancer.
  • Epigenetic modifications are reversible, making them attractive therapeutic targets.

Purpose of the Study:

  • To review recent literature on protein complexes catalyzing epigenetic modifications.
  • To discuss inhibitors of these complexes as cancer drug candidates.
  • To highlight promising epigenetic targets lacking current inhibitors.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of protein complexes involved in epigenetic regulation.

Related Experiment Videos

  • Examination of existing and potential therapeutic inhibitors.

    • Main Results:

    • Identified key protein complexes responsible for epigenetic modifications.
    • Cataloged inhibitors currently in development for cancer therapy.
    • Highlighted epigenetic modifiers with therapeutic potential but no available inhibitors.

    Conclusions:

    • Epigenetic modifiers are crucial in cancer and represent viable therapeutic targets.
    • Inhibitors targeting epigenetic complexes offer reversible treatment options.
    • Further research is needed to develop inhibitors for promising, yet untargeted, epigenetic modifiers.